BridgeMD
New treatment option for Geographic Atrophy (GA)
Official title Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
ClinicalTrials.gov ID: NCT07230834
What this study is testing
What is Pozelimab?
Pozelimab is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for geographic atrophy (ga).
Also referred to as REGN3918.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Study eye with diagnosis of GA of the macula secondary to AMD, as determined by the investigator
- Study eye with total GA area measuring approximately one disc area or greater in size (2.5 mm\^2 or larger) at screening, as determined by the...
- Best-Corrected Visual Acuity (BCVA) of 60 letters or worse using the Early Treatment Diabetic Retinopathy Score (ETDRS) charts (Snellen equivalent of...
You likely can't join if
- GA (macular atrophy) in either eye due to causes other than dry AMD
- History or current evidence of macular neovascularization and/or retinal exudation in either eye
- Concurrent eye disease (elevated Intraocular Pressure (IOP) \>25mm Hg, diabetic retinopathy, ocular infections/inflammation)
- Prior or current intravitreal (IVT) treatment of any kind for any indication in either the study or fellow eye, except complement inhibitor therapy...
- Any prior systemic treatment for dry AMD, except oral supplements or vitamins
- History or current use of systemic complement inhibitor therapy Note: Other protocol-defined Inclusion/ Exclusion criteria apply
The study team makes the final eligibility decision.
Where it's taking place
- Lakewood, Colorado, United States
- East Weymouth, Massachusetts, United States
- Austin, Texas, United States
- Dallas, Texas, United States
- The Woodlands, Texas, United States
- Tbilisi, Georgia
- Bucharest, Romania
- Cluj-Napoca, Romania
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lakewood, Colorado, United States; East Weymouth, Massachusetts, United States; Austin, Texas, United States; Dallas, Texas, United States; The Woodlands, Texas, United States; Tbilisi, Georgia and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.